Cargando…

CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case–control study

INTRODUCTION: CYP17 is the second most important enzyme in estradiol synthesis. Epidemiological studies have shown the associations between CYP17 polymorphisms and cancer risk. We conducted a case–control study to evaluate the relationship between CYP17 polymorphisms (rs743572 and rs2486758) and bre...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Pengtao, Wang, Meng, Tian, Tian, Feng, Yanjing, Zheng, Yi, Yang, Tielin, Li, Hongtao, Lin, Shuai, Xu, Peng, Deng, Yujiao, Hao, Qian, Li, Na, Guan, Feng, Dai, Zhijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037160/
https://www.ncbi.nlm.nih.gov/pubmed/30013390
http://dx.doi.org/10.2147/CMAR.S167503
_version_ 1783338291193446400
author Yang, Pengtao
Wang, Meng
Tian, Tian
Feng, Yanjing
Zheng, Yi
Yang, Tielin
Li, Hongtao
Lin, Shuai
Xu, Peng
Deng, Yujiao
Hao, Qian
Li, Na
Guan, Feng
Dai, Zhijun
author_facet Yang, Pengtao
Wang, Meng
Tian, Tian
Feng, Yanjing
Zheng, Yi
Yang, Tielin
Li, Hongtao
Lin, Shuai
Xu, Peng
Deng, Yujiao
Hao, Qian
Li, Na
Guan, Feng
Dai, Zhijun
author_sort Yang, Pengtao
collection PubMed
description INTRODUCTION: CYP17 is the second most important enzyme in estradiol synthesis. Epidemiological studies have shown the associations between CYP17 polymorphisms and cancer risk. We conducted a case–control study to evaluate the relationship between CYP17 polymorphisms (rs743572 and rs2486758) and breast cancer (BC) risk. PATIENTS AND METHODS: This case–control study included 560 BC patients and 583 age-matched healthy controls from Northwest China. Two polymorphisms (rs743572 and rs2486758) of CYP17 were genotyped by using Sequenom MassARRAY. ORs and 95% CIs were used to evaluate the relationship. RESULTS: Compared with the wild genotype of rs743572, we found a significantly reduced risk of BC associated with the variant genotypes (heterozygote model: OR=0.69, 95% CI=0.53–0.89; homozygote model: OR=0.68, 95% CI=0.49–0.95; dominant model: OR=0.69, 95% CI=0.54–0.87; overdominant model: OR=0.78, 95% CI=0.62–0.98; allele model: OR=0.79, 95% CI=0.66–0.93). For rs2486758 polymorphism, we did not find any difference in any of the genetic models. Further stratification analysis by clinical characteristics showed rs743572 was associated with estrogen receptor status (heterozygote model: OR=2.13, 95% CI=1.47–3.08; homozygote model: OR=3.29, 95% CI=1.94–5.58; dominant model: OR=2.39, 95% CI=1.69–3.37) and progesterone receptor status (homozygote model: OR=3.17, 95% CI=1.82–5.55), but there was no association between rs2486758 and clinical characteristics of BC. Haplotype analysis showed that G(rs743572)C(rs2486758) haplotype was a protective factor of BC (OR=0.52, 95% CI=0.40–0.67). Survival analysis did not find that CYP17 rs743572 polymorphism was associated with triple-negative BC, either in terms of overall survival or progression-free survival. CONCLUSION: Our results suggest that CYP17 polymorphisms may reduce the susceptibility to BC in Chinese women.
format Online
Article
Text
id pubmed-6037160
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-60371602018-07-16 CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case–control study Yang, Pengtao Wang, Meng Tian, Tian Feng, Yanjing Zheng, Yi Yang, Tielin Li, Hongtao Lin, Shuai Xu, Peng Deng, Yujiao Hao, Qian Li, Na Guan, Feng Dai, Zhijun Cancer Manag Res Original Research INTRODUCTION: CYP17 is the second most important enzyme in estradiol synthesis. Epidemiological studies have shown the associations between CYP17 polymorphisms and cancer risk. We conducted a case–control study to evaluate the relationship between CYP17 polymorphisms (rs743572 and rs2486758) and breast cancer (BC) risk. PATIENTS AND METHODS: This case–control study included 560 BC patients and 583 age-matched healthy controls from Northwest China. Two polymorphisms (rs743572 and rs2486758) of CYP17 were genotyped by using Sequenom MassARRAY. ORs and 95% CIs were used to evaluate the relationship. RESULTS: Compared with the wild genotype of rs743572, we found a significantly reduced risk of BC associated with the variant genotypes (heterozygote model: OR=0.69, 95% CI=0.53–0.89; homozygote model: OR=0.68, 95% CI=0.49–0.95; dominant model: OR=0.69, 95% CI=0.54–0.87; overdominant model: OR=0.78, 95% CI=0.62–0.98; allele model: OR=0.79, 95% CI=0.66–0.93). For rs2486758 polymorphism, we did not find any difference in any of the genetic models. Further stratification analysis by clinical characteristics showed rs743572 was associated with estrogen receptor status (heterozygote model: OR=2.13, 95% CI=1.47–3.08; homozygote model: OR=3.29, 95% CI=1.94–5.58; dominant model: OR=2.39, 95% CI=1.69–3.37) and progesterone receptor status (homozygote model: OR=3.17, 95% CI=1.82–5.55), but there was no association between rs2486758 and clinical characteristics of BC. Haplotype analysis showed that G(rs743572)C(rs2486758) haplotype was a protective factor of BC (OR=0.52, 95% CI=0.40–0.67). Survival analysis did not find that CYP17 rs743572 polymorphism was associated with triple-negative BC, either in terms of overall survival or progression-free survival. CONCLUSION: Our results suggest that CYP17 polymorphisms may reduce the susceptibility to BC in Chinese women. Dove Medical Press 2018-07-03 /pmc/articles/PMC6037160/ /pubmed/30013390 http://dx.doi.org/10.2147/CMAR.S167503 Text en © 2018 Yang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Yang, Pengtao
Wang, Meng
Tian, Tian
Feng, Yanjing
Zheng, Yi
Yang, Tielin
Li, Hongtao
Lin, Shuai
Xu, Peng
Deng, Yujiao
Hao, Qian
Li, Na
Guan, Feng
Dai, Zhijun
CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case–control study
title CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case–control study
title_full CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case–control study
title_fullStr CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case–control study
title_full_unstemmed CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case–control study
title_short CYP17 polymorphisms are associated with decreased risk of breast cancer in Chinese Han women: a case–control study
title_sort cyp17 polymorphisms are associated with decreased risk of breast cancer in chinese han women: a case–control study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037160/
https://www.ncbi.nlm.nih.gov/pubmed/30013390
http://dx.doi.org/10.2147/CMAR.S167503
work_keys_str_mv AT yangpengtao cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT wangmeng cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT tiantian cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT fengyanjing cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT zhengyi cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT yangtielin cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT lihongtao cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT linshuai cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT xupeng cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT dengyujiao cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT haoqian cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT lina cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT guanfeng cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy
AT daizhijun cyp17polymorphismsareassociatedwithdecreasedriskofbreastcancerinchinesehanwomenacasecontrolstudy